Genetic Readies for Growth Post Acquisition by Renaissance and Aurora
Deal News | May 20, 2025 | Finance Community IT - 3 Private Equity
CVC Strategic Opportunities, along with the Pavese family, has agreed to sell its entire stake in Genetic, a leading CDMO based in Salerno, Italy, to NB Renaissance and NB Aurora. The transaction, which awaits closing in the third quarter of 2025, will see Renaissance and Aurora become shareholders alongside the Pavese family, who intend to increase their stake. The transaction advisors include Mediobanca, BNP Paribas, JP Morgan, and Vitale, among others. After the acquisition, the plan is to enhance Genetic's production capabilities and expand its market reach, focusing on complex drug development, both in generic and proprietary formulations. Genetic, which serves a global client base, is renowned for its sterile manufacturing techniques and hopes to further its presence internationally while maintaining its commitment to providing accessible healthcare solutions.
Sectors
- Pharmaceuticals
- Private Equity
- Healthcare
Geography
- Italy – Genetic is headquartered in Salerno, Italy, and the transaction involves Italian stakeholders and targets the growth of Genetic within this geography.
Industry
- Pharmaceuticals – This industry is relevant because Genetic is a Contract Development and Manufacturing Organization (CDMO) serving pharmaceutical companies with drug development and manufacturing services.
- Private Equity – The transaction involves private equity firms NB Renaissance and NB Aurora acquiring stakes in Genetic, highlighting the relevance of the private equity industry.
- Healthcare – Genetic is involved in healthcare by providing medical and therapeutic solutions through drug development and manufacturing, aligning with healthcare industry dynamics.
Financials
- – The article does not specify financial details such as deal price or target revenue.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Genetic | Target Company | Company | A pharmaceutical CDMO specializing in drug development and manufacturing, with a focus on complex generic molecules and advanced production techniques. |
| CVC Strategic Opportunities | Selling Company | Company | A private equity firm exiting its stake in Genetic as part of the transaction. |
| NB Renaissance | Bidding Company | Company | A private equity firm acquiring an interest in Genetic to support its future growth. |
| NB Aurora | Bidding Company | Company | A growth capital firm purchasing interest in Genetic, aiding its expansion plans. |
| Pavese Family | Participant | People | Founders and significant stakeholders in Genetic will retain and increase their ownership in the company. |
| Mediobanca | Lead Advisor | Company | Financial advisor to Renaissance and Aurora in the transaction. |
| Rothschild & Co. | Financial Advisor | Company | Financial advisor to CVC in the transaction. |
| Blackstone and CVC Credit | Financial Backers | Company | Entities providing financing for the transaction. |